Founded in 1998, Pharmaxis was listed on the Australian Stock Exchange in 2003 (symbol PXS). Headquartered in Sydney at its manufacturing facilities, Pharmaxis has grown to become among Australia's largest life sciences companies, with offices in the US, UK and China. In May 2009 Pharmaxis took possession of a new 7,000 square metre factory and headquarters in Frenchs Forest, Sydney, which provides the manufacturing capacity needed for the launch of Bronchitol to overseas markets.
Milestones
2010
Phase 1 clinical trial demonstrates PXS25 safe, well tolerated and a pharmacokinetic profile consistent with once per day delivery
Pharmaxis completes acquition of Topigen Pharmaceuticals Inc
2009
Short term Phase 2 cystic fibrosis dosing trial with Bronchitol returns positive results
Long term Phase 3 bronchiectasis trial demonstrates Bronchitol safe after 12 months treatment
Marketing application filed for Bronchitol in Australia
Submission of New Drug Application for Aridol to the FDA
Commencement of a second Phase 3 trial with Bronchitol in patients with cystic fibrosis
Pivotal Phase 3 trial in patients with cystic fibrosis demonstrates that Bronchitol is safe and effective
Completion of purpose built state of the art production facility in Sydney, Australia
Completion of $54 million capital raising to new and existing investors
Pharmaxis voluntarily de-lists from Nasdaq
Second Phase 3 trial in patients with cystic fibrosis passes recruitment target
Commencement of pivotol Phase 3 bronchiectasis clinical trial
Submission of application to market Bronchitol for cystic fibrosis in Europe
FDA Advisory Committee recommends approval of Aridol
Sustained benefit of Bronchitol in Phase 3 cystic fibrosis trial
Pharmaxis receives response letter from FDA on Aridol application